Watson Bio 61 days waist cut, the average loss of shareholders is 520,000 (with intelligent analysis report) The latest market stocks and CSI 300 trend comparison historical dividend core index fluctuations Valuation analysis Market sentiment and public opinion analysis AI helps read massive research report agency performance forecast agency rating agency reviews

On November 5, international pharmaceutical giant Pfizer said that the new crown oral drug under development reduced the risk of hospitalization or death by 89%, and as soon as the news came out, the US stocks anti-epidemic concept stocks fell, and a share was affected by this: On November 8, vaccine stocks represented by CanSino, Watson Bio, and Fosun Pharmaceutical fell by more than 6% intraday.

For Watson Biologics, since the high of 96.73 yuan on August 5 this year, the stock price has been falling and falling, falling to 47.69 yuan today. In 61 trading days, Watson Bio fell by 50.69%, and the total market value evaporated by 70 billion, and it is estimated that 133,700 shareholders have lost more than 520,000 yuan per capita.

The sharp correction in Watson's stock price may be related to 2 reasons.

First, the early stage has risen more, and there is a demand for corrections. Since the beginning of the year, Watson Bio has entered the main rising wave, and the stock price has risen from a high of near 33 yuan to 96.73 yuan, an increase of more than 193%. Some funds do not rule out choosing to take profits at a high level, resulting in a downward trend in the stock price.

Second, the heat of vaccine stocks has cooled down. Since July, individual stocks such as CanSino, Watson Bio, and Fosun Pharmaceutical have gradually peaked, and the sector has collectively pulled back.

Related information: Yunnan Watson Biotechnology Co., Ltd. was founded in 2001, is a domestic specializing in vaccines, blood products and other biological drugs research and development, production, sales of modern biopharmaceutical enterprises, for the national recognition of high-tech enterprises and national enterprise technology center. The company was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange of China in November 2010 (stock abbreviation: Watson Bio; stock code: 300142).

Appendix: Watson Bio-Intelligent Individual Stock Analysis Report (September 1, 10:00am)

According to the quantitative trading model, the current stock price trend is relatively weak, but the price difference between the stock price and the CSI 300 has increased, indicating that although the current stock price is still in the downward stage, but the stock price relative to the CSI 300 has signs of acceleration, with the gradual increase of the stock price and the CSI 300 price difference, driving the stock price to form growth momentum, you can combine the fundamental indicators and short-term technical indicators to reasonably open positions, do a good job of risk control and dynamic position adjustment, rational decision-making, scientific investment.

Since 2018, Watson Bio has implemented 3 cash dividends. The cumulative net profit was 2,049,391,300 yuan, of which the cumulative dividend amount in the dividend year was 124,432,500 yuan. (The latest period of 2020 attributable net profit was 1,003,186,800 yuan, and the dividend amount was 78,309,300 yuan, with a dividend ratio of 7.81%.) ）

Financial Analysis: The financial position has been enhanced

1. Industry valuation comparison

From the perspective of industry valuation, only peg and ps in the current dynamic valuation indicators of Watson Bio are lower than the industry average, and the stock price has a certain probability of being relatively overvalued, so it remains cautious.

<col>

name

Market Capitalization (100 million)

pe (times)

peg (times)

pb (times)

pcf (times)

ps (times)

Watson Bio

793.53

87.97

0.07

10.11

307.6

23.42

2. Valuation trend analysis

From the perspective of its own valuation trend, PB, PCF and ps in the current valuation indicators of Watson Bio are at a relatively low level in the past year; pe and peg are at a relatively balanced level in the past year.

Industry comparison

As of 2021-11-08, a total of 19 institutions have made forecasts for Watson Bio's 2023 annual results within 6 months; it predicts earnings per share of 1.46 yuan in 2023, an annual growth rate of 16.47%, and predicts that the net profit in 2023 will be 2.284 billion yuan, an annual growth rate of 17.38%.

In the past 6 months, 3 research reports have rated Watson Biologics, with 67% of the recommended overweight, and the comprehensive rating is "overweight"

Institutional Reviews - Highlights (Last 6 Months)

●Focus on cutting-edge technology

●Advance layout of a new generation of nucleic acid drugs

●Worked with Aibo Biologics to create the first domestic RNA vaccine

●International sales icing on the cake

Risk Warning - Key Points (Last 6 Months)

●R&D work relies heavily on the capabilities of the company's R&D team

●There is a possibility that R&D will not be as expected

● There are few successful examples to refer to

● Research and development is not as expected: the sequence design and delivery system of RNA vaccines are cutting-edge technology

Note: The appendix part is from the Yun tianyi financial data textualization project, which is automatically generated by ai.